New hope for lung cancer patients when first treatment fails
NCT ID NCT00532155
First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 24 times
Summary
This study tested whether adding a drug called aflibercept to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer when their first treatment stops working. Over 900 participants received either the new combination or chemotherapy plus a placebo. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi-Aventis Administraive Office
Istanbul, Turkey (Türkiye)
-
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, 08807, United States
-
Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
-
Sanofi-Aventis Administrative Office
Vienna, Austria
-
Sanofi-Aventis Administrative Office
São Paulo, Brazil
-
Sanofi-Aventis Administrative Office
Sofia, Bulgaria
-
Sanofi-Aventis Administrative Office
Laval, Canada
-
Sanofi-Aventis Administrative Office
Santiago, Chile
-
Sanofi-Aventis Administrative Office
Shanghai, China
-
Sanofi-Aventis Administrative Office
Prague, Czechia
-
Sanofi-Aventis Administrative Office
Tallinn, Estonia
-
Sanofi-Aventis Administrative Office
Helsinki, Finland
-
Sanofi-Aventis Administrative Office
Paris, France
-
Sanofi-Aventis Administrative Office
Berlin, Germany
-
Sanofi-Aventis Administrative Office
Athens, Greece
-
Sanofi-Aventis Administrative Office
Causeway Bay, Hong Kong
-
Sanofi-Aventis Administrative Office
Budapest, Hungary
-
Sanofi-Aventis Administrative Office
Mumbai, India
-
Sanofi-Aventis Administrative Office
Milan, Italy
-
Sanofi-Aventis Administrative Office
Kuala Lumpur, Malaysia
-
Sanofi-Aventis Administrative Office
Gouda, Netherlands
-
Sanofi-Aventis Administrative Office
Warsaw, Poland
-
Sanofi-Aventis Administrative Office
Porto Salvo, Portugal
-
Sanofi-Aventis Administrative Office
Bucharest, Romania
-
Sanofi-Aventis Administrative Office
Moscow, Russia
-
Sanofi-Aventis Administrative Office
Singapore, Singapore
-
Sanofi-Aventis Administrative Office
Seoul, South Korea
-
Sanofi-Aventis Administrative Office
Barcelona, Spain
-
Sanofi-Aventis Administrative Office
Bromma, Sweden
-
Sanofi-Aventis Administrative Office
Taipei, Taiwan
-
Sanofi-Aventis Admnistrative Office
Guildford Surrey, United Kingdom
-
sanofi-aventis Australia & New Zealand administrative office
Macquarie Park, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.